Global Benchmark: Approved SUD Medications (2016–2026) Review

Global Evidence on Approved SUD Medications (2016–2026)

A 2026 umbrella review registered on PROSPERO (ID: CRD420251036330) consolidates global evidence from systematic reviews and phase 3 randomized controlled trials (RCTs) on approved pharmacotherapies for substance use disorders (SUD). Drawing from 16 systematic reviews, 371 RCTs (n = 131,965), and 62 observational studies (n = 229,225), the review covers 41 approved medications (25 distinct molecules) for alcohol, opioid, tobacco, and sedative-hypnotic/anxiolytic use disorders worldwide. This synthesis provides the most comprehensive benchmark to date for SUD medication efficacy and informs the evaluation of emerging therapies, including psychedelics.

The review includes only medications approved by World Health Organization (WHO)-listed authorities or regulators in the ten most populous countries, ensuring global relevance. Phase 3 RCTs with posted results from 2016 to 2026 were included, and methodological rigor was maintained using the ROBIS, AMSTAR-2, and RoB2 tools. The findings are presented by medication and SUD subtype, offering detailed comparative data for clinicians, researchers, and policymakers.

Mechanisms, Efficacy, and Real-World Outcomes

Approved SUD medications demonstrate variable efficacy across different substance categories, with notable differences in abstinence and relapse rates. For alcohol use disorder (AUD), 86 RCTs (n = 18,643) covering seven medications showed a reduction in the risk of returning to any drinking ranging from 7% to 17% compared to placebo. This modest effect size underscores the persistent challenge of relapse in AUD, even with pharmacotherapy.

For opioid use disorder (OUD), 49 RCTs (n = 7,804) and 21 observational studies (n = 155,111) covering 12 medications reported the highest abstinence rates of 41–43% (versus 5% for placebo). Opioid overdose reversal agents, examined in 41 observational studies (n = 74,114), achieved survival rates of 92–98%, reflecting the critical role of medications like naloxone in acute care. Tobacco use disorder (TUD) was addressed in 223 RCTs (n = 104,524) covering eight medications, with abstinence rates 1.3–2.3 times higher than placebo, but long-term quit rates remain suboptimal.

Notably, only one medication was identified for sedative-hypnotic or anxiolytic use disorder (SHAUD) in 13 RCTs (n = 994), highlighting a significant gap in approved pharmacotherapies for benzodiazepine and related substance misuse. Four completed phase 3 RCTs with posted results (n = 1,026) examined pipeline medications for AUD and stimulant use disorder (StUD), but no new approvals for psychedelics or novel mechanisms were reported as of January 2026.

Policy, Research, and Clinical Implications

The umbrella review's findings serve as a critical benchmark for evaluating the potential of emerging interventions, including psychedelic-based treatments, in the SUD landscape. Policymakers and regulators can use this evidence to identify areas of unmet need—particularly in stimulant and sedative use disorders, where few effective medications exist. The modest efficacy of current AUD and TUD medications further underscores the need for innovation in these domains.

For researchers, the detailed breakdown of efficacy by substance and medication type provides a reference point for designing and interpreting future trials. Importantly, the review highlights that real-world effectiveness often lags behind RCT outcomes, especially in populations with comorbidities or limited access to integrated care. This gap between trial efficacy and real-world impact is a crucial, often overlooked, factor when considering the translation of new therapies into practice.

Clinicians gain a synthesized, up-to-date resource to inform shared decision-making with patients and to contextualize the promise and limitations of existing pharmacotherapies. For those developing psychedelic or other novel interventions, the review clarifies regulatory expectations for comparative efficacy and safety, as new treatments will be judged against these established benchmarks in future approval processes.

Risks, Limitations, and Unmet Needs

Current SUD medications, while effective for some, leave substantial populations underserved due to limited efficacy, side effects, or lack of options for certain substances. The review notes that abstinence rates for AUD and TUD remain low, and that medication adherence and retention in care are persistent challenges. For OUD, while opioid agonists and antagonists improve outcomes, barriers to access and stigma still limit their public health impact.

A critical insight from the review is the paucity of approved medications for stimulant and sedative use disorders, despite rising global prevalence and associated morbidity. The absence of robust phase 3 data for these indications signals both a research gap and a regulatory hurdle for innovators. Moreover, the review's reliance on published and registered data may underrepresent negative or inconclusive findings, a common limitation in meta-analyses and umbrella reviews.

Looking Forward: Implications for Psychedelic and Novel Therapies

The comprehensive synthesis of global SUD pharmacotherapy outcomes establishes a transparent efficacy threshold for future interventions, including psychedelic-assisted treatments. As new compounds move through clinical pipelines, they will need to demonstrate not only statistical superiority to placebo but also meaningful benefits over established medications in real-world settings.

For funders, institutions, and field stakeholders, the review highlights both the urgent need for innovation in underserved SUD categories and the regulatory rigor required for approval. The findings suggest that successful new therapies must address both efficacy and implementation challenges—such as adherence, accessibility, and comorbidity management—to achieve meaningful public health impact. As the field evolves, ongoing, transparent benchmarking against established standards will be essential for guiding investment, policy, and clinical adoption.

How we research: Reviewed and synthesized by Dr. Alex R. Hensley, MD, MSc, Addiction Medicine and Clinical Trials Editor. Reviewed by Dr. Hensley on 2026-09-25. Primary source: OpenAlex record; PROSPERO registration CRD420251036330.